New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 6, 2014
07:33 EDTADXSAdvaxis announces presentation of updated ADXS-cHER2 data
Advaxis announced that its principal investigator presented updated data from the ongoing ADXS-cHER2 study in canine osteosarcoma at the 2014 American College of Veterinary Internal Medicine Forum. The preliminary findings of the Phase 1 clinical trial in dogs with osteosarcoma suggest that ADXS-cHER2 is safe and well tolerated at doses up to 3 x 109 CFU with no evidence of cardiac, hematological, or other systemic toxicities. The study determined that ADXS-cHER2 is able to delay or prevent metastatic disease and significantly prolong overall survival in dogs with osteosarcoma that had minimal residual disease following standard of care. At the time of the presentation, 80% of the dogs treated were still alive and median survival had not yet been reached. Median survival in control dogs was 316 days. Immunological analyses are also being conducted in this study to further evaluate the immune response to ADXS-cHER2. Recently, ADXS-cHER2 was granted orphan drug status for the treatment of human osteosarcoma by the U.S. Food and Drug Administration Office of Orphan Products Development.
News For ADXS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 22, 2014
09:24 EDTADXSOn The Fly: Pre-market Movers
HIGHER: Caesars Entertainment (CZR), up 23.8% following agreement to merge with Caesars Acquisition (CACQ)... Synthetic Biologics (SYN), up 8.6% following positive topline results from SYN-004 Phase 1a trial... Advaxis (ADXS), up 6.1% after Adage Capital Partners reports 18.84% passive stake in Advaxis... TASER (TASR), up 4.25% following multiple orders of Smart Weapons and Conducted Electrical Weapons... BioCryst Pharmaceuticals (BCRX), up 3.4% after RAPIVAB receives FDA approval... Herbalife (HLF), up 1.4% following a New York Post report that the FDA asked the company to stop airing a video claiming FDA approval. LOWER: Ocwen Financial (OCN), down 10.5% following settlement agreement with New York Department of Financial Services. NOTABLE: Enanta Pharmaceuticals (ENTA), up 11.8% following FDA approval of AbbVie's Viekira Pak... AbbVie is (ABBV) is up 2.4% following FDA approval of Viekira Pak and that Express Scripts (ESRX) will expand access to Viekira Pak... Express Scripts is trading marginally higher... Gilead Sciences (GILD), down 11.3% after Express Scripts picks AbbVie for hepatitis C.
December 19, 2014
16:26 EDTADXSAdage Capital Partners reports 18.84% passive stake in Advaxis
Subscribe for More Information
December 15, 2014
07:33 EDTADXSAdvaxis announces FDA acceptance of INDA to commence clinical trials of ADXS-HPV
Subscribe for More Information
December 8, 2014
09:20 EDTADXSOn The Fly: Pre-market Movers
Subscribe for More Information
07:35 EDTADXSAdvaxis reports FDA acceptance of IND application for ADXS-PSA combination trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use